167 related articles for article (PubMed ID: 2153347)
21. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
Sullivan PS; Apple SK
Breast J; 2009; 15(2):146-54. PubMed ID: 19292800
[TBL] [Abstract][Full Text] [Related]
22. [In situ determination of the Ki-67 growth fraction (Ki-67 GF) in human tumors (studies in breast cancer)].
Lellé RJ
Acta Histochem Suppl; 1990; 39():109-24. PubMed ID: 2080254
[TBL] [Abstract][Full Text] [Related]
23. Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas.
Domagala W; Harezga B; Szadowska A; Markiewski M; Weber K; Osborn M
Am J Pathol; 1993 Mar; 142(3):669-74. PubMed ID: 8384406
[TBL] [Abstract][Full Text] [Related]
24. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
25. Vimentin expression in breast carcinomas.
Niveditha SR; Bajaj P
Indian J Pathol Microbiol; 2003 Oct; 46(4):579-84. PubMed ID: 15025348
[TBL] [Abstract][Full Text] [Related]
26. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
[TBL] [Abstract][Full Text] [Related]
27. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
[TBL] [Abstract][Full Text] [Related]
28. Expression of epidermal growth factor receptors (EGFR) on breast carcinomas in relation to growth fractions, estrogen receptor status and morphological criteria. An immunohistochemical study.
Wrba F; Reiner A; Ritzinger E; Holzner JH; Reiner G
Pathol Res Pract; 1988 Feb; 183(1):25-9. PubMed ID: 3362749
[TBL] [Abstract][Full Text] [Related]
29. Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1.
Rody A; Holtrich U; Gaetje R; Gehrmann M; Engels K; von Minckwitz G; Loibl S; Diallo-Danebrock R; Ruckhäberle E; Metzler D; Ahr A; Solbach C; Karn T; Kaufmann M
Clin Cancer Res; 2007 Feb; 13(4):1115-22. PubMed ID: 17317819
[TBL] [Abstract][Full Text] [Related]
30. Growth fractions and estrogen receptors in human breast cancers as determined in situ with monoclonal antibodies.
Gerdes J; Pickartz H; Brotherton J; Hammerstein J; Weitzel H; Stein H
Am J Pathol; 1987 Dec; 129(3):486-92. PubMed ID: 3501245
[TBL] [Abstract][Full Text] [Related]
31. Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53.
Guo LL; Gao P; Wu YG; Jian WC; Hao CY; Li H; Lin XY
Arch Med Res; 2007 Nov; 38(8):846-52. PubMed ID: 17923265
[TBL] [Abstract][Full Text] [Related]
32. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
[TBL] [Abstract][Full Text] [Related]
33. Moesin expression is associated with the estrogen receptor-negative breast cancer phenotype.
Carmeci C; Thompson DA; Kuang WW; Lightdale N; Furthmayr H; Weigel RJ
Surgery; 1998 Aug; 124(2):211-7. PubMed ID: 9706140
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.
Moinfar F; Okcu M; Tsybrovskyy O; Regitnig P; Lax SF; Weybora W; Ratschek M; Tavassoli FA; Denk H
Cancer; 2003 Aug; 98(4):703-11. PubMed ID: 12910513
[TBL] [Abstract][Full Text] [Related]
35. Morphologic and clinical aspects of estrogen receptors in carcinoma of the breast.
Kern WH
Surg Gynecol Obstet; 1979 Feb; 148(2):240-2. PubMed ID: 217114
[TBL] [Abstract][Full Text] [Related]
36. [Immunohistochemical evidence of vimentin in fibrocystic breast disease and mammary carcinoma].
Alexiev B; Valkov I; Popov A
Zentralbl Pathol; 1992 Sep; 138(4):284-8. PubMed ID: 1329942
[TBL] [Abstract][Full Text] [Related]
37. In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit.
Kommoss F; Colley M; Hart CE; Franklin WA
Mol Cell Probes; 1990 Feb; 4(1):11-23. PubMed ID: 1969111
[TBL] [Abstract][Full Text] [Related]
38. Estrogen and progesterone receptor expression and proliferation in breast cancer cells, studied with flow cytometry.
Scheres HM; Schutte B; De Goij AF; Bosman FT
Acta Histochem Suppl; 1990; 40():71-6. PubMed ID: 2091049
[No Abstract] [Full Text] [Related]
39. [Expression of ER and PgR in phase S in cells of breast carcinoma].
Simone G; Mangia A; Petroni S; Caponio MA; De Mola F; L'Abbate A; Sapia MG; Paradiso A; Wiesel S
Pathologica; 1992; 84(1094):71-4. PubMed ID: 1338653
[No Abstract] [Full Text] [Related]
40. Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia.
Shaaban AM; O'Neill PA; Davies MP; Sibson R; West CR; Smith PH; Foster CS
Am J Surg Pathol; 2003 Dec; 27(12):1502-12. PubMed ID: 14657709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
